Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Former Eli Lilly job applicants say the company's hiring practices favor the young
Not waving but drowning: Takeda's blood cancer drug flunks phase 3, dealing further blow to hopes of approval flurry
Healthcare Dealmakers—Ginger, Headspace's $3B merger; UnitedHealth Group and Change Healthcare's DOJ deal
First Biogen, now the FDA: Congressional Democrats request agency records over Aduhelm's approval
Bristol Myers greenlights neurodegenerative medicine from Evotec pact for $20M
Medicare's hospital fund is running out of money. Experts have 5 ideas on how to help
COVID test maker Cue Health takes aim at public debut with $100M IPO
Pfizer's COVID-19 booster application set for high-stakes FDA advisory committee review in 2 weeks
Hospitals stopped suing patients for unpaid medical debt after media exposure, public pressure, study suggests
Abbott gets its blood pumping by acquiring clot-removing devicemaker Walk Vascular
Cyberattacks against outpatient, specialty clinics on the rise as data breaches double from 2018
COVID-19 tracker: GSK requires US workers to be vaccinated; Moderna's shot produces more antibodies than Pfizer in elderly

Featured Story

Former Eli Lilly job applicants say the company's hiring practices favor the young

By Eric Sagonowsky

Following a high-profile CFO exit earlier this year and a discrimination lawsuit filed a month later, Eli Lilly is again in the spotlight for a personnel issue—this time for alleged age bias.

Not waving but drowning: Takeda's blood cancer drug flunks phase 3, dealing further blow to hopes of approval flurry

By Nick Paul Taylor

Takeda’s Wave 1 pipeline is threatening to peter out into a ripple. The latest setback comes from a phase 3 blood cancer clinical trial, which found adding pevonedistat to chemotherapy did nothing to improve event-free survival.

Healthcare Dealmakers—Ginger, Headspace's $3B merger; UnitedHealth Group and Change Healthcare's DOJ deal

By Dave Muoio

Carbon Health's expanding clinic footprint, Verily's first-ever purchase and more merger and acquisition news from the month of August.

First Biogen, now the FDA: Congressional Democrats request agency records over Aduhelm's approval

By Noah Higgins-Dunn

Months after high-ranking Democrats demanded Biogen answer for concerns shrouding its controversial Alzheimer’s drug Aduhelm, the pair of lawmakers are now making a similar request to the FDA itself, according to a letter sent to interim commissioner Janet Woodcock, M.D.

Bristol Myers greenlights neurodegenerative medicine from Evotec pact for $20M

By Annalee Armstrong

Evotec is headed to the bank with a cool $20 million after Bristol Myers Squibb opted in on a neurodegenerative medicine called EVT8683. The licensing opt-in could also trigger $250 million in milestone payments down the line plus royalties on future sales.

Medicare's hospital fund is running out of money. Experts have 5 ideas on how to help

By Robert King

Medicare's hospital fund is going to run out in five years and experts think the solution lies in new taxes and cuts to Medicare Advantage and certain providers.

COVID test maker Cue Health takes aim at public debut with $100M IPO

By Andrea Park

The IPO will support Cue’s previously expressed plans to expand its success in developing testing tools for COVID-19 into other diseases and conditions.

Pfizer's COVID-19 booster application set for high-stakes FDA advisory committee review in 2 weeks

By Eric Sagonowsky

Amid weeks of debate over COVID-19 boosters, the White House has released plans to quickly roll out follow-up shots while some experts have voiced serious concerns. At a meeting later this month, outside FDA vaccine advisers will get a chance to have their say.

Hospitals stopped suing patients for unpaid medical debt after media exposure, public pressure, study suggests

By Dave Muoio

Virginia hospitals filed 59% fewer medical debt lawsuits against patients in the wake of a published study and dozens of news articles highlighting their collections tactics, according to a recent review.

Abbott gets its blood pumping by acquiring clot-removing devicemaker Walk Vascular

By Andrea Park

Looking to grow its footprint in endovascular surgery, Abbott has taken a step forward by announcing its intent to acquire Walk Vascular.

Cyberattacks against outpatient, specialty clinics on the rise as data breaches double from 2018

By Garrison Wells

The neighborhood family clinic down the street is no longer safe from hackers. Healthcare data breaches are not only on the rise, but they are also spreading like a virus from hospitals to smaller provider facilities, a new report finds.

COVID-19 tracker: GSK requires US workers to be vaccinated; Moderna's shot produces more antibodies than Pfizer in elderly

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

GlaxoSmithKline will require U.S. workers to be vaccinated. A University of Virginia study shows Moderna's vaccine produces higher antibody counts than Pfizer's shot, especially among the elderly. A real-world study in Bangladesh shows that masks work. Plus more headlines.

PM Tracker